Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

Constitutive B-cell receptor signaling leads to overexpression of the antiapoptotic BCL-2 protein and is implicated in the pathogenesis of many types of B-cell non-Hodgkin lymphoma (B-NHL). The BCL-2 small-molecule inhibitor venetoclax shows promising clinical response rates in several lymphomas, but is not curative as monotherapy. Radiotherapy is a rational candidate for combining with BCL-2 inhibition, as DNA damage caused by radiotherapy increases the activity of pro-apoptotic BCL-2 pathway proteins, and lymphomas are exquisitely sensitive to radiation. We tested B-NHL responses to venetoclax combined with either external beam radiotherapy or radioimmunotherapy (RIT), which joins the selectivity of antibody targeting with the effectiveness of irradiation. We first tested cytotoxicity of cesium-137 irradiation plus venetoclax in 14 B-NHL cell lines representing five lymphoma subtypes. Combination treatment synergistically increased cell death in 10 of 14 lines. Lack of synergy was predicted by resistance to single-agent venetoclax and high BCL-XL expression. We then assessed the efficacy of external beam radiotherapy plus venetoclax in murine xenograft models of mantle cell (MCL), germinal-center diffuse large B-cell (GCB-DLBCL), and activated B-cell (ABC-DLBCL) lymphomas. In each model, external beam radiotherapy plus venetoclax synergistically increased mouse survival time, curing up to 10%. We finally combined venetoclax treatment of MCL and ABC-DLBCL xenografts with a pretargeted RIT (PRIT) system directed against the CD20 antigen. Optimal dosing of PRIT plus venetoclax cured 100% of mice with no detectable toxicity. Venetoclax combined with radiotherapy may be a promising treatment for a wide range of lymphomas Cancer Res; 77(14); 3885-93. ©2017 AACR.

[1]  M. Amiot,et al.  BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma , 2017, British journal of haematology.

[2]  P. Houghton,et al.  Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. , 2016, Blood.

[3]  J. Dipersio,et al.  Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. , 2016, Blood reviews.

[4]  D. Rizzieri.  Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? , 2016, Critical reviews in oncology/hematology.

[5]  P. Ghadjar,et al.  Radiotherapy for Non-Hodgkin’s lymphoma: still standard practice and not an outdated treatment option , 2016, Radiation oncology.

[6]  Yonghong Shi,et al.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. , 2016, Blood.

[7]  A. Gemma,et al.  Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. , 2016, Biochemical and biophysical research communications.

[8]  A. Al-Katib,et al.  Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting. , 2016, Nuclear medicine and biology.

[9]  R. Advani,et al.  Postibrutinib outcomes in patients with mantle cell lymphoma. , 2016, Blood.

[10]  M. Amiot,et al.  Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models , 2016, Molecular Cancer Therapeutics.

[11]  P. Martin.  Ibrutinib—a new standard treatment for relapsed mantle cell lymphoma? , 2016, The Lancet.

[12]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[13]  B. Sandmaier,et al.  Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. , 2016, Blood.

[14]  Marco A Marra,et al.  Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma. , 2016, Blood.

[15]  C. Flowers,et al.  The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era , 2016, Leukemia & lymphoma.

[16]  S. Lonial,et al.  Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax , 2015, Leukemia.

[17]  S. Cuzzocrea,et al.  90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity , 2015, Oncotarget.

[18]  S. Lonial,et al.  Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax , 2015, Oncogene.

[19]  A. Roberts,et al.  Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) , 2015 .

[20]  T. Kipps,et al.  A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma , 2015 .

[21]  D. Maloney,et al.  High‐dose CD20‐targeted radioimmunotherapy‐based autologous transplantation improves outcomes for persistent mantle cell lymphoma , 2015, British journal of haematology.

[22]  A. Ting,et al.  miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies , 2015, Molecular Cancer.

[23]  S. Larson,et al.  Radioimmunotherapy of human tumours , 2015, Nature Reviews. Cancer.

[24]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[25]  J. Friedberg,et al.  Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. , 2015, Future oncology.

[26]  Jeffrey A Jones,et al.  Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. , 2015, JAMA oncology.

[27]  B. Miller,et al.  Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models , 2015, PloS one.

[28]  S. Maïga,et al.  Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma , 2015, Oncotarget.

[29]  K. Plate,et al.  β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma , 2015, Molecular Cancer.

[30]  B. Wood,et al.  A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. , 2014, Cancer research.

[31]  K. Blum,et al.  Ibrutinib in B-cell Lymphomas , 2014, Current Treatment Options in Oncology.

[32]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[33]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[34]  Liang Xu,et al.  Drug Resistance and Molecular Cancer Therapy: Apoptosis Versus Autophagy , 2013 .

[35]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[36]  Ying-hua Jin,et al.  Phosphorylation of Rad9 at Serine 328 by Cyclin A-Cdk2 Triggers Apoptosis via Interfering Bcl-xL , 2012, PloS one.

[37]  P. Fink,et al.  Dietary Essential Amino Acids Affect the Reproduction of the Keystone Herbivore Daphnia pulex , 2011, PloS one.

[38]  V. Jendrossek.  The intrinsic apoptosis pathways as a target in anticancer therapy. , 2012, Current pharmaceutical biotechnology.

[39]  L. Staudt,et al.  Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.

[40]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[41]  A. Rohatiner,et al.  Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. , 2009, The oncologist.

[42]  J. Pagel,et al.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. , 2009, Blood.

[43]  F. Buchegger,et al.  Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. , 2008, The oncologist.

[44]  R. Lotan,et al.  Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy , 2007, Journal of biopharmaceutical statistics.

[45]  Boris Zhivotovsky,et al.  DNA damage-induced apoptosis , 2004, Oncogene.

[46]  C. Rödel,et al.  Radiotherapy for Stage I–III Nodal Low-Grade Non-Hodgkin’s Lymphoma , 2003, Strahlentherapie und Onkologie.

[47]  Damon L. Meyer,et al.  Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. , 2003, Blood.

[48]  Damon L. Meyer,et al.  Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  Damon L. Meyer,et al.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.

[50]  J. Ledbetter,et al.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer Immunology, Immunotherapy.

[51]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.